206 related articles for article (PubMed ID: 22300311)
1. Predictors of long-term visual outcome after chemoreduction for management of intraocular retinoblastoma.
Narang S; Mashayekhi A; Rudich D; Shields CL
Clin Exp Ophthalmol; 2012; 40(7):736-42. PubMed ID: 22300311
[TBL] [Abstract][Full Text] [Related]
2. Long-term visual outcome following chemoreduction for retinoblastoma.
Demirci H; Shields CL; Meadows AT; Shields JA
Arch Ophthalmol; 2005 Nov; 123(11):1525-30. PubMed ID: 16286614
[TBL] [Abstract][Full Text] [Related]
3. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation.
Gündüz K; Günalp I; Yalçindağ N; Unal E; Taçyildiz N; Erden E; Geyik PO
Ophthalmology; 2004 Oct; 111(10):1917-24. PubMed ID: 15465557
[TBL] [Abstract][Full Text] [Related]
4. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction.
Demirci H; Eagle RC; Shields CL; Shields JA
Arch Ophthalmol; 2003 Aug; 121(8):1125-31. PubMed ID: 12912690
[TBL] [Abstract][Full Text] [Related]
5. Chemoreduction for unilateral retinoblastoma.
Shields CL; Honavar SG; Meadows AT; Shields JA; Demirci H; Naduvilath TJ
Arch Ophthalmol; 2002 Dec; 120(12):1653-8. PubMed ID: 12470138
[TBL] [Abstract][Full Text] [Related]
6. Management and outcome of retinoblastoma with vitreous seeds.
Manjandavida FP; Honavar SG; Reddy VA; Khanna R
Ophthalmology; 2014 Feb; 121(2):517-24. PubMed ID: 24572675
[TBL] [Abstract][Full Text] [Related]
7. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes.
Shields CL; Ramasubramanian A; Thangappan A; Hartzell K; Leahey A; Meadows AT; Shields JA
Ophthalmology; 2009 Mar; 116(3):544-551.e1. PubMed ID: 19157557
[TBL] [Abstract][Full Text] [Related]
8. Chemoreduction improves eye retention in patients with retinoblastoma: a report from the German Retinoblastoma Reference Centre.
Künkele A; Jurklies C; Wieland R; Lohmann D; Bornfeld N; Eggert A; Schulte JH
Br J Ophthalmol; 2013 Oct; 97(10):1277-83. PubMed ID: 23863458
[TBL] [Abstract][Full Text] [Related]
9. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Ness S; Meadows AT; Shields JA
Arch Ophthalmol; 2005 Jun; 123(6):765-73. PubMed ID: 15955977
[TBL] [Abstract][Full Text] [Related]
10. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma.
Shields CL; Honavar SG; Shields JA; Demirci H; Meadows AT; Naduvilath TJ
Arch Ophthalmol; 2002 Apr; 120(4):460-4. PubMed ID: 11934319
[TBL] [Abstract][Full Text] [Related]
11. Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients.
Shields CL; Shelil A; Cater J; Meadows AT; Shields JA
Arch Ophthalmol; 2003 Nov; 121(11):1571-6. PubMed ID: 14609913
[TBL] [Abstract][Full Text] [Related]
12. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation.
Schefler AC; Cicciarelli N; Feuer W; Toledano S; Murray TG
Ophthalmology; 2007 Jan; 114(1):162-9. PubMed ID: 17070578
[TBL] [Abstract][Full Text] [Related]
13. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation.
Shields CL; Honavar SG; Meadows AT; Shields JA; Demirci H; Singh A; Friedman DL; Naduvilath TJ
Am J Ophthalmol; 2002 May; 133(5):657-64. PubMed ID: 11992863
[TBL] [Abstract][Full Text] [Related]
14. Intravenous chemoreduction or intra-arterial chemotherapy for cavitary retinoblastoma: long-term results.
Rojanaporn D; Kaliki S; Bianciotto CG; Iturralde JC; Say EA; Shields CL
Arch Ophthalmol; 2012 May; 130(5):585-90. PubMed ID: 22652844
[TBL] [Abstract][Full Text] [Related]
15. A 10-year experience of outcome in chemotherapy-treated hereditary retinoblastoma.
Bartuma K; Pal N; Kosek S; Holm S; All-Ericsson C
Acta Ophthalmol; 2014 Aug; 92(5):404-11. PubMed ID: 24119165
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma.
Zage PE; Reitman AJ; Seshadri R; Weinstein JL; Mets MB; Zeid JL; Greenwald MJ; Strauss LC; Goldman S
Pediatr Blood Cancer; 2008 Mar; 50(3):567-72. PubMed ID: 17729249
[TBL] [Abstract][Full Text] [Related]
17. Resolution of iris neovascularization following chemoreduction of retinoblastoma.
Patel J; Turaka K; Shields CL
J Pediatr Ophthalmol Strabismus; 2010 Oct; 47 Online():e1-3. PubMed ID: 21162463
[TBL] [Abstract][Full Text] [Related]
18. The International Classification of Retinoblastoma predicts chemoreduction success.
Shields CL; Mashayekhi A; Au AK; Czyz C; Leahey A; Meadows AT; Shields JA
Ophthalmology; 2006 Dec; 113(12):2276-80. PubMed ID: 16996605
[TBL] [Abstract][Full Text] [Related]
19. Comparison of retinoblastoma reduction for chemotherapy vs external beam radiotherapy.
Sussman DA; Escalona-Benz E; Benz MS; Hayden BC; Feuer W; Cicciarelli N; Toledano S; Markoe A; Murray TG
Arch Ophthalmol; 2003 Jul; 121(7):979-84. PubMed ID: 12860801
[TBL] [Abstract][Full Text] [Related]
20. Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors.
Shields CL; Mashayekhi A; Cater J; Shelil A; Meadows AT; Shields JA
Am J Ophthalmol; 2004 Sep; 138(3):329-37. PubMed ID: 15364213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]